Symbols / EVLO $0.00 +0.00% Evelo Biosciences, Inc.

Healthcare • Biotechnology • United States • PNK
EVLO Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 1.90K
Enterprise Value 16.69M
Income -82.35M
Sales —
FCF (ttm) -43.31M
Book/sh -1.42
Cash/sh 0.91
Employees 66
Insider 10d —
IPO May 09, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S —
P/B -0.00
P/C —
EV/EBITDA -0.24
EV/Sales —
Quick Ratio 0.43
Current Ratio 0.48
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.91
EPS next Y -1.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-11-09
Earnings (prior) 2023-11-09
ROA -83.25%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 18.98M
Shs Float 18.90M
Insider Own 0.00%
Instit Own 0.00%
Short Float 2.22%
Short Ratio 0.12
Short Interest 196.99K
52W High 0.00
vs 52W High -95.00%
52W Low 0.00
vs 52W Low 0.00%
Beta 1.67
Impl. Vol. —
Rel Volume 0.35
Avg Volume 381.00
Volume 133.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-41.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-10-18 down TD Cowen Outperform → Market Perform —
2023-07-26 main Morgan Stanley Equal-Weight → Equal-Weight $10
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
Operating Revenue
0.00
0.00
Operating Expense
108.47
-6.01%
115.40
Research And Development
78.55
-6.08%
83.64
Selling General And Administration
29.91
-5.80%
31.75
General And Administrative Expense
29.91
-5.80%
31.75
Salaries And Wages
19.36
-1.28%
19.61
Other Gand A
10.55
-13.10%
12.14
Total Expenses
108.47
-6.01%
115.40
Operating Income
-108.47
+6.01%
-115.40
Total Operating Income As Reported
-108.47
+6.01%
-115.40
EBITDA
-106.86
+7.81%
-115.92
Normalized EBITDA
-106.34
+5.63%
-112.69
Reconciled Depreciation
2.06
-7.04%
2.22
EBIT
-108.92
+7.80%
-118.14
Total Unusual Items
-0.52
+83.88%
-3.23
Total Unusual Items Excluding Goodwill
-0.52
+83.88%
-3.23
Special Income Charges
-0.52
+83.88%
-3.23
Other Special Charges
0.52
-83.88%
3.23
Net Income
-114.53
+6.26%
-122.18
Pretax Income
-113.60
+6.69%
-121.75
Net Non Operating Interest Income Expense
-4.67
-29.35%
-3.61
Interest Expense Non Operating
4.67
+29.35%
3.61
Net Interest Income
-4.67
-29.35%
-3.61
Interest Expense
4.67
+29.35%
3.61
Other Income Expense
-0.46
+83.25%
-2.74
Other Non Operating Income Expenses
0.06
-87.45%
0.49
Tax Provision
0.93
+117.29%
0.43
Tax Rate For Calcs
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
-0.11
+87.46%
-0.87
Net Income Including Noncontrolling Interests
-114.53
+6.26%
-122.18
Net Income From Continuing Operation Net Minority Interest
-114.53
+6.26%
-122.18
Net Income From Continuing And Discontinued Operation
-114.53
+6.26%
-122.18
Net Income Continuous Operations
-114.53
+6.26%
-122.18
Normalized Income
-114.12
+4.76%
-119.82
Net Income Common Stockholders
-114.53
+6.26%
-122.18
Diluted EPS
-26.20
+43.29%
-46.20
Basic EPS
-26.20
+43.29%
-46.20
Basic Average Shares
4.36
+64.75%
2.65
Diluted Average Shares
4.36
+64.75%
2.65
Diluted NI Availto Com Stockholders
-114.53
+6.26%
-122.18
Line Item Trend 2022-12-31 2021-12-31
Total Assets
64.44
-26.66%
87.87
Current Assets
51.57
-27.39%
71.03
Cash Cash Equivalents And Short Term Investments
47.94
-29.95%
68.44
Cash And Cash Equivalents
47.94
-29.95%
68.44
Cash Equivalents
46.66
-30.35%
66.99
Cash Financial
1.28
-11.85%
1.45
Prepaid Assets
—
2.58
Other Current Assets
3.63
+40.54%
2.58
Total Non Current Assets
12.87
-23.61%
16.84
Net PPE
11.71
-24.61%
15.53
Gross PPE
21.05
-9.16%
23.17
Accumulated Depreciation
-9.34
-22.28%
-7.63
Properties
0.00
0.00
Buildings And Improvements
6.87
-22.92%
8.91
Machinery Furniture Equipment
1.14
+4.41%
1.09
Construction In Progress
1.12
-15.06%
1.32
Other Properties
9.76
+0.74%
9.69
Leases
2.16
+0.00%
2.16
Other Non Current Assets
1.16
-11.81%
1.31
Total Liabilities Net Minority Interest
69.43
-12.34%
79.20
Current Liabilities
12.39
-28.61%
17.36
Payables And Accrued Expenses
8.52
+3.16%
8.26
Payables
1.76
+10.18%
1.60
Accounts Payable
1.76
+10.18%
1.60
Current Accrued Expenses
6.75
+1.47%
6.66
Pensionand Other Post Retirement Benefit Plans Current
1.19
-81.43%
6.41
Current Debt And Capital Lease Obligation
2.26
+15.79%
1.95
Current Capital Lease Obligation
2.26
+15.79%
1.95
Other Current Liabilities
0.43
-42.45%
0.74
Total Non Current Liabilities Net Minority Interest
57.04
-7.77%
61.84
Long Term Debt And Capital Lease Obligation
48.88
-10.05%
54.34
Long Term Debt
43.61
-6.32%
46.56
Long Term Capital Lease Obligation
5.26
-32.37%
7.79
Non Current Deferred Liabilities
7.50
+0.00%
7.50
Non Current Deferred Revenue
7.50
+0.00%
7.50
Other Non Current Liabilities
0.66
—
Stockholders Equity
-4.99
-157.60%
8.67
Common Stock Equity
-4.99
-157.60%
8.67
Capital Stock
0.11
+105.56%
0.05
Common Stock
0.11
+105.56%
0.05
Preferred Stock
0.00
0.00
Share Issued
5.54
+106.91%
2.68
Ordinary Shares Number
5.54
+106.91%
2.68
Additional Paid In Capital
524.12
+23.82%
423.31
Retained Earnings
-529.22
-27.62%
-414.69
Total Equity Gross Minority Interest
-4.99
-157.60%
8.67
Total Capitalization
38.62
-30.06%
55.22
Working Capital
39.18
-26.99%
53.66
Invested Capital
38.62
-30.06%
55.22
Total Debt
51.14
-9.16%
56.29
Capital Lease Obligations
7.52
-22.72%
9.74
Net Tangible Assets
-4.99
-157.60%
8.67
Tangible Book Value
-4.99
-157.60%
8.67
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-101.23
-4.66%
-96.72
Cash Flow From Continuing Operating Activities
-101.23
-4.66%
-96.72
Net Income From Continuing Operations
-114.53
+6.26%
-122.18
Depreciation Amortization Depletion
2.06
-7.04%
2.22
Depreciation
2.06
-7.04%
2.22
Depreciation And Amortization
2.06
-7.04%
2.22
Other Non Cash Items
4.39
+108.66%
2.10
Stock Based Compensation
15.16
-4.34%
15.85
Operating Gains Losses
1.35
-57.94%
3.22
Net Foreign Currency Exchange Gain Loss
0.41
0.00
Gain Loss On Sale Of PPE
0.42
+6128.57%
-0.01
Change In Working Capital
-9.67
-567.41%
2.07
Change In Prepaid Assets
-1.16
-86.17%
-0.62
Change In Payables And Accrued Expense
-5.44
-109.23%
-2.60
Change In Accrued Expense
-5.61
-103.34%
-2.76
Change In Payable
0.17
+6.92%
0.16
Change In Account Payable
0.17
+6.92%
0.16
Change In Other Working Capital
—
7.50
Change In Other Current Liabilities
-3.07
-38.85%
-2.21
Investing Cash Flow
-0.62
+58.00%
-1.48
Cash Flow From Continuing Investing Activities
-0.62
+58.00%
-1.48
Net PPE Purchase And Sale
-0.62
+58.00%
-1.48
Purchase Of PPE
-0.62
+59.05%
-1.52
Sale Of PPE
0.00
-100.00%
0.04
Capital Expenditure
-0.62
+59.05%
-1.52
Financing Cash Flow
81.66
-16.29%
97.54
Cash Flow From Continuing Financing Activities
81.66
-16.29%
97.54
Net Issuance Payments Of Debt
-3.12
-121.13%
14.78
Issuance Of Debt
44.49
+201.04%
14.78
Repayment Of Debt
-47.61
0.00
Long Term Debt Issuance
44.49
+201.04%
14.78
Long Term Debt Payments
-47.61
0.00
Net Long Term Debt Issuance
-3.12
-121.13%
14.78
Net Common Stock Issuance
84.54
+3.42%
81.75
Proceeds From Stock Option Exercised
0.23
-76.85%
1.01
Changes In Cash
-20.20
-2933.33%
-0.67
Effect Of Exchange Rate Changes
-0.45
0.00
Beginning Cash Position
69.75
-0.95%
70.42
End Cash Position
49.10
-29.61%
69.75
Free Cash Flow
-101.86
-3.68%
-98.24
Interest Paid Supplemental Data
4.22
+24.81%
3.38
Income Tax Paid Supplemental Data
0.63
+2432.00%
0.03
Common Stock Issuance
84.54
+3.42%
81.75
Issuance Of Capital Stock
84.54
+3.42%
81.75
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category